Nuevolution signs agreement with Boehringer
The drugs which will be discovered will target the diseases that interest to Boehringer. As per the terms of the agreement, Nuevolution is responsible to get an upfront
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.